EUVIMEDEUVIMED entdecken
Crossref

Engineered Artesunate-Naphthalimide Hybrid Dual Drug for Synergistic Multimodal Therapy against Experimental Murine Lymphoma

Debapriya RoyMahapatra, Ranjeet Singh, Ugir Hossain Sk iD, Partha Pratim Manna iD

Molecular Pharmaceutics · 2024

DOI: 10.1021/acs.molpharmaceut.3c00632 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Debapriya RoyMahapatra und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Translational Research, Chittaranjan National Cancer Institute, Kolkata 700 026, West Bengal, India. Hauptthemen laut MEDLINE: Neoplasms, Lymphoma, Antineoplastic Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Indian Council of Medical Research, Chittaranjan National Cancer Institute, Ministry of Human Resource Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lymphoma can effectively be treated with a chemotherapy regimen that is associated with adverse side effects due to increasing drug resistance, so there is an emergent need for alternative small-molecule inhibitors to overcome the resistance that occurs in lymphoma management and overall increase the prognosis rate. A new series of substituted naphthalimide moieties conjugated via ester and amide linkages with artesunate were designed, synthesized, and characterized. In addition to the conjugates, to further achieve a theranostic molecule, FITC was incorporated via a multistep synthesis process. DNA binding studies of these selected derivatives by ultraviolet-visible (UV-vis), fluorescence spectroscopy, intercalating dye (EtBr, acridine orange)-DNA competitive assay, and minor groove binding dye Hoechst 33342-DNA competitive assay suggested that the synthesized novel molecules intercalated between the two strands of DNA due to its naphthalimide moiety and its counterpart artesunate binds with the minor groove of DNA. Napthalimide-artesunate conjugates inhibit the growth of lymphoma and induce apoptosis, including ready incorporation and reduction in cell viability. The remodeled drug has a significant tumoricidal effect against solid DL tumors developed in BALB/c mice in a dose-dependent manner. The novel drug appears to inhibit metastasis and increase the survival of the treated animals compared with untreated littermates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsLymphomaAntineoplastic AgentsAnimalsMiceArtesunateNaphthalimidesDNASpectrometry, FluorescenceApoptosis

Stichwörter der Autor:innen

DL lymphomaapoptosisartesunatehybrid drugnaphthalimidetumoricidal activity

Substanzen

ArtesunateNaphthalimidesDNAAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Clinical and Translational Research, Chittaranjan National Cancer Institute, Kolkata 700 026, West Bengal, India.
  • Immunobiology Laboratory, Department of Zoology, Institute of Science, Banaras Hindu University, Varanasi 221005, India.

ORCID-Profile: Ugir Hossain Sk, Partha Pratim Manna

Förderung

  • Indian Council of Medical Research
  • Chittaranjan National Cancer Institute
  • Ministry of Human Resource Development
  • Human Resource Development Group

Zitieren

APA

RoyMahapatra, D., Singh, R., Sk, U. H., & Manna, P. P. (2024). Engineered Artesunate-Naphthalimide Hybrid Dual Drug for Synergistic Multimodal Therapy against Experimental Murine Lymphoma. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.3c00632

Vancouver

RoyMahapatra D, Singh R, Sk UH, Manna PP. Engineered Artesunate-Naphthalimide Hybrid Dual Drug for Synergistic Multimodal Therapy against Experimental Murine Lymphoma. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.3c00632

BibTeX
@article{RoyMahapatra2024,
  author = {RoyMahapatra, Debapriya and Singh, Ranjeet and Sk, Ugir Hossain and Manna, Partha Pratim},
  title = {Engineered Artesunate-Naphthalimide Hybrid Dual Drug for Synergistic Multimodal Therapy against Experimental Murine Lymphoma},
  journal = {Molecular Pharmaceutics},
  year = {2024},
  doi = {10.1021/acs.molpharmaceut.3c00632}
}
Kostenlos starten →